Chromatin/Epigenetics
Chromatin/epigenetics inhibitors are compounds that modulate the structure and function of chromatin or interfere with epigenetic modifications, such as DNA methylation and histone modification. These inhibitors are essential tools for studying gene expression regulation and the role of epigenetics in diseases like cancer, neurological disorders, and developmental abnormalities. By targeting epigenetic processes, these inhibitors can alter gene expression patterns and offer new therapeutic avenues. At CymitQuimica, we provide a wide selection of high-quality chromatin/epigenetics inhibitors to support your research in molecular biology, genetics, and epigenetics.
Subcategories of "Chromatin/Epigenetics"
Found 2235 products of "Chromatin/Epigenetics"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
TC-A 2317 hydrochloride
CAS:<p>TC-A 2317 HCl inhibits Aurora A kinase (Ki 1.2 nM) over Aurora B (Ki 101 nM), displaying antitumor effects.</p>Formula:C19H29ClN6OPurity:98%Color and Shape:SolidMolecular weight:392.93TC-AC28
CAS:<p>TC-AC28 is a novel potent and selective Brd2(2) ligand.</p>Formula:C23H21N5O3Purity:98%Color and Shape:SolidMolecular weight:415.44Nesuparib
CAS:<p>Nesuparib, a potent PARP/TNKS1 inhibitor, has antitumor properties and potential for treating various diseases.</p>Formula:C23H24N6OPurity:99.71%Color and Shape:SolidMolecular weight:400.48GSK4028
CAS:<p>GSK4028 is the enantiomeric negative control of GSK4027, a PCAF/GCN5 bromodomain chemical probe, with a pIC50 of 4.9 in a TR-FRET assay.</p>Formula:C17H21BrN4OColor and Shape:SolidMolecular weight:377.28HL23
CAS:<p>HL23 is a histone deacetylase (HDAC) inhibitor that effectively targets hepatocellular carcinoma (HCC).</p>Formula:C44H44N2O7Purity:98%Color and Shape:SolidMolecular weight:712.83BRD4 Inhibitor-23
CAS:<p>BRD4 Inhibitor-23: potent, oral, IC50: BRD4 BD-1 6.21 nM, BD-2 1.44 nM. See WO2022033542A1 Example 1.</p>Formula:C22H19F2N3O4SColor and Shape:SolidMolecular weight:459.47HIF-2α-IN-6
CAS:<p>HIF-2α-IN-6 (117) is a HIF-2α inhibitor [1].</p>Formula:C15H13F4NO3SColor and Shape:SolidMolecular weight:363.33TCS 21311
CAS:<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Formula:C27H25F3N4O4Purity:99.39% - ≥98%Color and Shape:SolidMolecular weight:526.51AMPK-IN-1
CAS:<p>AMPK-IN-1 is an activator of the AMP-activated protein kinase (AMPK) enzyme, specifically targeting the α2β2γ1 isoform with an EC50 of 551 nM.</p>Formula:C24H18ClN3O3Color and Shape:SolidMolecular weight:431.87EPZ011989 HCl(1598383-40-4 Free base)
CAS:<p>EPZ011989 is a highly potent and selective oral EZH2 inhibitor with Ki value <3 nM.</p>Formula:C35H51N5O4·HClColor and Shape:SolidMolecular weight:642.27TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Formula:C17H11ClF2N4O2Color and Shape:SolidMolecular weight:376.74CBP/p300-IN-19
CAS:<p>CBP/p300-IN-19 inhibits p300/CBP HAT (IC50: 1.4μM), less effective on PCAF/Myst3, shows anti-tumor properties.</p>Formula:C30H27N3O3Color and Shape:SolidMolecular weight:477.55GSK2646264
CAS:<p>GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.</p>Formula:C24H26N2O2Color and Shape:SolidMolecular weight:374.48Gö 7874
CAS:<p>Gö 7874 is a potent, reversible, ATP-competitive, and selective inhibitor of protein kinase C (IC50 = 4 nM for rat brain PKC).</p>Formula:C27H26N4O4Color and Shape:SolidMolecular weight:470.52HSP70/SIRT2-IN-2
CAS:<p>HSP70/SIRT2-IN-2 (Compounds 1a), a dual inhibitor of SIRT2 and HSP70, exhibits an IC50 of 45.1±5.0 μM against SIRT2 and demonstrates antitumor activity [1].</p>Formula:C17H13N3S3Purity:98%Color and Shape:SolidMolecular weight:355.5LY3295668
CAS:<p>LY3295668 (AK-01) is a selective inhibitor of Aurora A with Kis of 0.8 nM and 1038 nM for Aurora A and B, respectively.</p>Formula:C24H26ClF2N5O2Purity:99.68%Color and Shape:SolidMolecular weight:489.95GNE-375
CAS:<p>GNE-375 is a selective and potent BRD9 inhibitor (IC50: 5 nM).GNE-375 inhibits BRD4, TAF1, and CECR2, and can be used to study epigenetic resistance.</p>Formula:C25H29N3O5Purity:98.99%Color and Shape:SolidMolecular weight:451.51HIF-2α agonist 2
CAS:<p>HIF-2α agonist 2 is an HIF-2α agonist with an EC50 value of 1.68 μM for HIF-2α.</p>Formula:C13H8Br2N2O2SPurity:98.87%Color and Shape:SoildMolecular weight:416.09EPZ031686
CAS:<p>EPZ031686 is an effective inhibitor of SMYD3 inhibitor with an IC50 of 3 nM and can be used in studies about cancer.</p>Formula:C26H34ClF3N4O4SPurity:99.67%Color and Shape:SolidMolecular weight:591.09E7016
CAS:<p>E7016 (GPI 21016) is an orally available PARP inhibitor. E7016 inhibits of DNA repair. E7016 can enhance tumor cell radiosensitivity in vitro and in vivo.</p>Formula:C20H19N3O3Purity:99.02%Color and Shape:SolidMolecular weight:349.38CPI-0610 carboxylic acid
CAS:<p>CPI-0610 carboxylic acid is a selective BET protein inhibitor with potential anticancer effects.</p>Formula:C20H15ClN2O3Purity:98.62%Color and Shape:SolidMolecular weight:366.8JAK-IN-3
CAS:<p>JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.</p>Formula:C18H20N4O3Purity:98.04% - 98.19%Color and Shape:SolidMolecular weight:340.38NPAS3-IN-1
CAS:<p>NPAS3-IN-1 is an NPAS3-ARNT heterodimerization inhibitor that regulates NPAS3 transcription by modulating the heterodimerization of NPAS3 with ARNT.</p>Formula:C10H5N3O2S3Purity:99.56%Color and Shape:SolidMolecular weight:295.36hRIO2 kinase ligand-1
CAS:<p>hRIO2 kinase ligand-1 is a potent ligand for hRIO2 kinase (Kd: 520 nM).</p>Formula:C17H14N2OPurity:99.89%Color and Shape:SolidMolecular weight:262.31CCT129202
CAS:<p>CCT129202 is an ATP-competitive pan-Aurora inhibitor for Aurora A, Aurora B and Aurora C with IC50 of 0.042 μM, 0.198 μM and 0.227 μM, respectively.</p>Formula:C23H25ClN8OSPurity:98.14%Color and Shape:SolidMolecular weight:497.02KDM4-IN-4
CAS:<p>KDM4-IN-4 is a KDM4 inhibitor with anticancer activity that inhibits the KDM4A-Tudor structural domain for cancer research.</p>Formula:C16H23NOPurity:99.61%Color and Shape:SolidMolecular weight:245.36AU-15330
CAS:<p>AU-15330 is a proteolytic targeting chimera (PROTAC) that simultaneously targets SMARCA4, SMARCA2, and PBRM1 for degradation and exhibits cytotoxicity in H3.3K27M cells but not in H3 wild-type cells. Cost-effective and quality-assured.</p>Formula:C39H49N9O5SPurity:98.21% - 99.62%Color and Shape:SolidMolecular weight:755.93PARP-1-IN-4
CAS:<p>PARP-1-IN-4 is a potent PARP-1 inhibitor with potential see anti-tumor activity, and inhibition of PARP-1 may be used in cancer development.</p>Formula:C22H15Cl2N3O2Purity:99.82%Color and Shape:SolidMolecular weight:424.28FHT-1015
CAS:<p>FHT-1205 is a potent inhibitor (IC50 ≤ 10 nM) of SMARCA4/SMARCA2 ATPase (BRG1 and BRM).</p>Formula:C25H25N5O4S3Purity:98.57%Color and Shape:SolidMolecular weight:555.69HS94
CAS:<p>HS94 (DAPK3 inhibitor HS94) is a selective and potent DAPK3 inhibitor with a Ki value of 126 nM for Pim kinase inhibition and can be used to study hypertension.</p>Formula:C15H15N5O2SPurity:95.04%Color and Shape:SolidMolecular weight:329.38Y06137
CAS:<p>Y06137, selective BET inhibitor, Kd 81 nM for BRD4(1), researched for castration-resistant prostate cancer treatment.</p>Formula:C27H32N4O2Purity:99.85%Color and Shape:SolidMolecular weight:444.57CeMMEC1
CAS:<p>CeMMEC1 is an inhibitor of BRD4, and also has a great affinity for TAF1(IC50=0.9 μM).</p>Formula:C19H16N2O4Purity:98.9% - 99.92%Color and Shape:SolidMolecular weight:336.34Aurora B inhibitor 1
CAS:<p>Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor (Ki <0.010 uM) with potential anticancer activity for cancer research.</p>Formula:C25H26ClF2N7O2Purity:98.37%Color and Shape:SolidMolecular weight:529.97L-Moses dihydrochloride
<p>L-Moses (L-45) dihydrochloride is the first, potent, selective p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor (Kd: 126 nM).</p>Formula:C21H26Cl2N6Color and Shape:SolidMolecular weight:433.38MC2652
<p>MC2652, a potent LSD1 inhibitor, suppresses leukemia (MV4-11, NB4) and impedes prostate cancer (LNCaP) cell growth.</p>Formula:C22H20N2OColor and Shape:SolidMolecular weight:328.41KDOAM-25 citrate
CAS:<p>KDOAM-25 citrate inhibits KDM5A/B/C/D (IC50: 71, 19, 69, 69 nM); boosts H3K4 methylation, hinders MM1S cell growth. [1]</p>Formula:C21H33N5O9Purity:98%Color and Shape:SolidMolecular weight:499.51BSI-401
CAS:<p>BSI-401 is an oral inhibitor of PARP-1. It can inhibit pancreatic cancer either when used alone or in synergy with Oxaliplatin.</p>Formula:C9H4INO4Color and Shape:SolidMolecular weight:317.037HDAC6-IN-13
<p>HDAC6-IN-13: potent, selective HDAC6 inhibitor; oral; IC50=0.019μM; targets HDAC1/2/3; crosses blood-brain barrier; anti-inflammatory.</p>Formula:C23H22N4OColor and Shape:SolidMolecular weight:370.45DS-9300
CAS:<p>DS-9300, an orally administered potent and selective inhibitor of EP300/CBP HAT, exhibits a significant inhibitory activity with an IC50 value of 28 nM.</p>Formula:C25H26F3N5O3Color and Shape:SolidMolecular weight:501.506K465
CAS:<p>6K465 is a potent Aurora A kinase inhibitor that reduces c-MYC and N-MYC oncoproteins, showing antiproliferative effects in SCLC and breast cancer cell lines.</p>Formula:C26H33ClFN9OPurity:99.78%Color and Shape:SolidMolecular weight:542.05Balomenib
CAS:<p>Balomenib is an inhibitor of the menin-MLL interaction, effectively blocking the men1-MLL4-43 interaction with an IC50 of less than 0.075 μM. It inhibits cell growth in MV4-11 (CC50 < 0.1 μM), MOLM-13 (CC50 0.1~0.5 μM), and HEK293 (CC50 < 2 μM) cells. Balomenib also exhibits antitumor activity.</p>Formula:C33H34F3N7O2Color and Shape:SolidMolecular weight:617.664O6BTG-C8-αGlu
CAS:<p>O6BTG-C8-αGlu is an O6-methylguanine-DNA methyltransferase (MGMT) inhibitor with an IC50 of 0.45 μM. At a concentration of 0.1 μM, it fully inhibits MGMT in HeLaS3 cells and demonstrates no cytotoxicity even at prolonged high doses (up to 20 μM). This compound is suitable for research on MGMT-related cancers.</p>Formula:C24H34BrN5O7SColor and Shape:SolidMolecular weight:616.525KH-259
<p>KH-259: potent, selective CNS-penetrant HDAC6 inhibitor with 0.26 μM IC50; shows antidepressant effects in mice.</p>Formula:C20H25N3O2Color and Shape:SolidMolecular weight:339.43BRD4-IN-7
CAS:<p>BRD4-IN-7, also known as compound 120, acts as a BRD4 inhibitor.</p>Formula:C29H24F2N4O3Color and Shape:SolidMolecular weight:514.52PAD2-IN-1 hydrochloride
<p>PAD2-IN-1 hydrochloride: potent, selective PAD2 inhibitor; 95x less on PAD4, 79x less on PAD3; benzimidazole derivative.</p>Formula:C25H30ClFN6O3Color and Shape:SolidMolecular weight:517PRMT5-IN-50
CAS:<p>PRMT5-IN-50 is an orally active selective inhibitor of PRMT5, demonstrating good metabolic stability and low clearance in human liver microsomes. It inhibits SDMA/HCT116-MTAPdel and SDMA/HCT116-MTAPwt with IC50 values for symmetric arginine methylation inhibition at 1.0 and 536 nM, respectively, and antiproliferative IC50 values at 19 and 1620 nM, respectively. Additionally, PRMT5-IN-50 suppresses tumor growth in mice.</p>Formula:C26H23F3N6OColor and Shape:SolidMolecular weight:492.496WIZ degrader 8
CAS:<p>WIZ degrader 8 (compound 10) is a potent and selective molecular glue degrader of the transcription factor WIZ, effectively inducing HbF expression. It promotes WIZ degradation and HbF induction, suggesting its potential use as an inhibitor for sickle cell disease.</p>Formula:C21H27N3O4Color and Shape:SolidMolecular weight:385.457BRD4 Inhibitor-33
CAS:<p>BRD4 Inhibitor-33 (example 13), a potent inhibitor of BRD4, is applicable in research related to both acute and chronic kidney diseases [1].</p>Formula:C24H20N4O2Color and Shape:SolidMolecular weight:396.44MAT2A-IN-19
CAS:<p>MAT2A-IN-19 (Compound I-3) is an inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 32.93 nM.</p>Formula:C23H15F5N6O3Color and Shape:SolidMolecular weight:518.396JPHM-2-167
CAS:<p>PHM-2-167 (Compound 11) is a selective inhibitor of the prolyl hydroxylase domain enzyme (PHD). It inhibits PHD2 and PHD3 with IC50 values of 0.253 μM and 3.95 μM, respectively. PHM-2-167 is applicable for research in chronic kidney disease.</p>Formula:C30H28N6O2Color and Shape:SolidMolecular weight:504.582MAT2A-IN-16
CAS:<p>MAT2A-IN-16 is a MAT2A inhibitor that effectively suppresses the proliferation of MTAP-/-HCT-116 cells, with an IC50 value of 20 nM.</p>Formula:C23H17ClN6OColor and Shape:SolidMolecular weight:428.874LSD1/2-IN-4
<p>LSD1/2-IN-4, a PCPA derivative, inhibits LSD1 (Ki 0.11 μM) & LSD2 (Ki 130 μM), potentially useful in T-cell leukemia research.</p>Formula:C9H8BrF2NColor and Shape:SolidMolecular weight:248.07PRMT5-IN-49
CAS:<p>PRMT5-IN-49 (Compound 4b16) is an inhibitor of PRMT5.</p>Formula:C19H22N2O2Color and Shape:SolidMolecular weight:310.39MAT2A-IN-18
CAS:<p>MAT2A-IN-18 (Compound 15) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of 50 nM or less.</p>Formula:C17H13ClN4OColor and Shape:SolidMolecular weight:324.764JAK1-IN-9
CAS:<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Formula:C16H13IN6Color and Shape:SolidMolecular weight:416.22NSD2-PWWP1-IN-1
CAS:<p>NSD2-PWWP1-IN-1 (compound 31) is a potent inhibitor of NSD2-PWWP1 with an IC50 value of 0.64 µM, demonstrating potential applications in cancer research.</p>Formula:C28H30N4Color and Shape:SolidMolecular weight:422.565NSD2-PWWP1-IN-2
CAS:<p>NSD2-PWWP1-IN-2 (compound 33) is a potent NSD2-PWWP1 inhibitor, exhibiting an IC50 value of 1.49 µM, indicating its potential utility in cancer research.</p>Formula:C29H30N4Color and Shape:SolidMolecular weight:434.575MAT2A-IN-21
CAS:<p>MAT2A-IN-21 (compound 28) is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 49 nM. It selectively inhibits cancer cells with MTAP deficiency.</p>Formula:C26H20F2N4O2Color and Shape:SolidMolecular weight:458.459MAT2A-IN-20
CAS:<p>MAT2A-IN-20 (Compound A49) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of ≤50 nM. It also inhibits human UGT1A1 with an IC50 of 28.45 μM. Additionally, MAT2A-IN-20 exhibits antitumor activity in mouse models.</p>Formula:C26H24F2N6O4Color and Shape:SolidMolecular weight:522.503HDAC-IN-27
<p>HDAC-IN-27 is a potent and orally active inhibitor of HDAC Class I (0.43 nM - 3.01 nM for HDAC1-3).</p>Formula:C20H22N4O2Color and Shape:SolidMolecular weight:350.41(rac)-Talazoparib
CAS:<p>(rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is an orally active inhibitor of PARP1/2, with Ki values of 1.2 nM and 0.87 nM, respectively. It inhibits cellular PARylation at an EC50 of 2.51 nM. This compound leads to the accumulation of DNA damage and suppresses the proliferation of BRCA1/2-mutated MX-1 and Capan-1 cells, with IC50 values of 0.3 nM and 5 nM, respectively. Additionally, (rac)-Talazoparib exhibits antitumor activity in mouse models.</p>Formula:C19H14F2N6OColor and Shape:SolidMolecular weight:380.3515-AIQ hydrochloride
CAS:<p>5-AIQ hydrochloride is a water-soluble PARP-1 inhibitor and serves as a vital functional group in various medications. It mitigates tissue damage associated with hepatic ischemia-reperfusion, making it valuable for research into conditions related to liver ischemia-reperfusion.</p>Formula:C9H9ClN2OColor and Shape:SolidMolecular weight:196.634NVS-BPTF-1
CAS:<p>NVS-BPTF-1 is a specific inhibitor of bromodomain and PHD finger containing transcription factor (BPTF), exhibiting a dissociation constant (K_D) of 71 nM [1].</p>Formula:C26H28FN7O3SColor and Shape:SolidMolecular weight:537.61SRI-43265
CAS:<p>SRI-43265 (compound 40) inhibits the dimerization of human antigen R protein (HuR), which is involved in cancer and inflammation pathogenesis [1].</p>Formula:C19H20N6OColor and Shape:SolidMolecular weight:348.4MAT2A-IN-17
CAS:<p>MAT2A-IN-17 is a potent inhibitor of MAT2A, with an IC50 of less than 100 nM. MAT2A-IN-17 is applicable in cancer research.</p>Formula:C23H18F3N7OColor and Shape:SolidMolecular weight:465.431HDAC1-IN-3
<p>HDAC1-IN-3 is a potent inhibitor of Pf HDAC1.</p>Formula:C22H24ClN7O2Color and Shape:SolidMolecular weight:453.92BET/Aurora kinase-IN-1
CAS:<p>BET/Aurora kinase-IN-1 (Compound 38) is a dual inhibitor of BET and Aurora kinases. It exhibits antiproliferative activity against various tumor cell lines and demonstrates significant antitumor efficacy in xenograft models of renal cell carcinoma and colon cancer, with tumor growth inhibition (TGI) rates of 45.99% and 53.06%, respectively.</p>Formula:C25H30FN7OColor and Shape:SolidMolecular weight:463.55HDAC-IN-87
CAS:<p>HDAC-IN-87 (Compound XII6) is a non-selective HDAC inhibitor with pIC50 values of 6.9 for HDAC4 and 5.8 for HDAC6. It exhibits fungicidal activity against P. sorghi and P. pachyrhizi. The acute oral LD50 in both male and female rats is greater than 500 mg/kg.</p>Formula:C13H7F5N4O2SColor and Shape:SolidMolecular weight:378.277HYDAMTIQ
CAS:<p>HYDAMTIQ, a PARP-1/2 inhibitor (IC 50 : 29-38 nM), exhibits a range of pharmacological effects including anticancer, anti-inflammatory, and ischemic protective properties. It effectively reduces pulmonary PARP activity and alleviates symptoms such as allergen-induced cough and dyspnea while also diminishing bronchial hyperresponsiveness to methacholine. Moreover, HYDAMTIQ shows potent tumor suppressor activity in various cancers such as ovarian, breast, prostate, pancreatic, and glioblastoma multiforme. Demonstrating in vivo efficacy, HYDAMTIQ has been tested in animal models for conditions like cerebral ischemia, asthma, and cancer [1].</p>Formula:C14H14N2O2SColor and Shape:SolidMolecular weight:274.34BRD4 D1-IN-1
<p>BRD4 D1-IN-1 selectively inhibits BRD4 D1 (IC50 <0.092 μM, Kd 18 nM) with >500-fold specificity versus D2.</p>Formula:C32H37F3N6OColor and Shape:SolidMolecular weight:578.67PHD2-IN-4
CAS:<p>PHD2-IN-4 (compound 1) is an inhibitor of PHD2, with an IC50 of 4 nM. It is utilized in research related to chronic kidney disease.</p>Formula:C21H19N5O3Color and Shape:SolidMolecular weight:389.407SARS-CoV-2 nsp14-IN-1
<p>SARS-CoV-2 nsp14-IN-1 inhibits Nsp14 Mtase with an IC50 of 0.061 μM, affecting multiple substrates.</p>Formula:C20H20N6O5SColor and Shape:SolidMolecular weight:456.48SIRT-IN-6
CAS:<p>SIRT-IN-6 (Compound 14) is a pan-inhibitor of SIRT1/2/3 with an IC50 value of >50 μM. It shows potential as a research agent for studies involving metabolic disorders, inflammation, cancer, and neurodegenerative diseases.</p>Formula:C7H4ClN3OSColor and Shape:SolidMolecular weight:213.644Milpecitinib
CAS:<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Formula:C20H20N4O2SColor and Shape:SolidMolecular weight:380.463HDAC11-IN-2
CAS:<p>HDAC11-IN-2 (compound B6) is a highly selective inhibitor of Histone Deacetylase 11 (HDAC11). It demonstrates IC50 values of 51.1 ×10^-3 μM for HDAC11 and 5 μM for HDAC8. HDAC11-IN-2 reduces de novo lipogenesis (DNL) and enhances fatty acid oxidation, which alleviates hepatic lipid accumulation and pathological symptoms in MASLD mice. By inhibiting HDAC11, HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at the Thr172 site, thereby modulating de novo lipogenesis and fatty acid oxidation in the liver.</p>Formula:C25H35N3O3Color and Shape:SolidMolecular weight:425.564PRMT5-IN-48
CAS:<p>PRMT5-IN-48 (compound D3) is an orally active PRMT5 inhibitor with an IC50 of 20.7 nM, displaying antitumor activity. It effectively suppresses the growth of various cancer cells, induces apoptosis, and causes cell cycle arrest at the G0/G1 phase. PRMT5-IN-48 is applicable for research in non-Hodgkin's lymphoma (NHL).</p>Formula:C30H37N5O3Color and Shape:SolidMolecular weight:515.646GSK3368715 3HCl
CAS:<p>GSK3368715, a potent inhibitor of type I protein arginine methyltransferases (PRMT), could inhibit PRMT1, 3, 4, 6 and 8 with Kiapp vaules ranging from 1.5 to 81</p>Formula:C20H41Cl3N4O2Purity:98%Color and Shape:SolidMolecular weight:475.92DS79932728
CAS:<p>DS79932728 is an orally active inhibitor of G9a and GLP, with IC50 values of 12.6 nM and 75.7 nM, respectively. It induces the production of γ-globin, thereby increasing fetal hemoglobin (HbF) levels. In cynomolgus monkey models, DS79932728 enhances the proportion of F-reticulocytes (F-rets) and shows good oral absorption characteristics.</p>Formula:C19H25N3OColor and Shape:SolidMolecular weight:311.421JAK3-IN-7
CAS:<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Formula:C17H20N6OPurity:98.81%Color and Shape:SolidMolecular weight:324.38LNK01004
CAS:<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Formula:C26H31N7O2Color and Shape:SolidMolecular weight:473.57HIF-2α-IN-5
CAS:<p>HIF-2α-IN-5 is a potent HIF-2α inhibitor with an IC 50 of < 50 nM [1].</p>Formula:C15H12F4O3S2Color and Shape:SolidMolecular weight:380.38PRMT5-IN-37
CAS:<p>PRMT5-IN-37 (compound 29), an orally active inhibitor of PRMT5, is utilized for cancer research.</p>Formula:C21H15F4N5O2Color and Shape:SolidMolecular weight:445.37JTZ-951 HCl
CAS:<p>JTZ-951 is a potent and orally active inhibitor of hypoxia inducible factor prolyl hydroxylase (PHD).</p>Formula:C17H17ClN4O4Purity:98%Color and Shape:SolidMolecular weight:376.79lirucitinib
CAS:<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Formula:C16H25N5OSColor and Shape:SolidMolecular weight:335.468FY-56
<p>FY-56: potent, selective LSD1/KDM1A inhibitor (IC50=42nM); differentiates MOLM-13/MV4-11 cells; promising for AML research.</p>Formula:C23H19FN2O3Color and Shape:SolidMolecular weight:390.41DDO-3055
CAS:<p>DDO-3055 is an orally active PHD2 inhibitor utilized in studies related to anemia associated with chronic kidney disease.</p>Formula:C17H13ClN2O5Color and Shape:SolidMolecular weight:360.749LSD1-IN-39
CAS:<p>LSD1-IN-39 (Compound 14) is a reversible inhibitor of LSD1 with an IC50 of 0.18 μM, showing broad-spectrum antiproliferative activity against cancer cells, inhibiting HepG2 cell migration, and suppressing epithelial-mesenchymal transition. Additionally, LSD1-IN-39 exhibits antitumor activity in mouse models.</p>Formula:C25H30N2O7Color and Shape:SolidMolecular weight:470.515AMPK activator 16
CAS:<p>AMPK activator16 (compound 6) functions as an AMP-activated protein kinase (AMPK) inhibitor. It interacts effectively with crucial AMPK residues, significantly activating the enzyme. In N2a cells, AMPK activator16 enhances the expression of phosphorylated AMPK (p-AMPK) and its downstream signaling proteins, such as phosphorylated ACC (Acetyl-CoA Carboxylase) and phosphorylated raptor (p-raptor).</p>Formula:C23H20ClNO5SColor and Shape:SolidMolecular weight:457.927CREB-IN-1 TFA
<p>CREB-IN-1 TFA: Potent oral CREB inhibitor, IC50 of 0.18 μM, suppresses breast cancer cell growth.</p>Color and Shape:SolidSTR-V-53
CAS:<p>STR-V-53, an HDAC inhibitor (IC50 in nM), increases histone acetylation in tumor cells by inhibiting these enzymes, thereby regulating gene expression. STR-V-53 inhibits tumor growth and induces apoptosis [1].</p>Formula:C21H30N4O8Color and Shape:SolidMolecular weight:466.48Purinostat
CAS:<p>Purinostat is a selective inhibitor of HDACI/IIb with potential anti-leukemic properties. Its mesylate form, Purinostat mesylate, is effective at inhibiting the survival of Ph+ leukemic cells and CD34+ leukemic cells derived from CML patients. Purinostat mesylate targets HDACI/IIb, impacting several crucial factors for leukemia stem cell (LSC) survival, such as c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR. Additionally, Purinostat mesylate enhances glutamate metabolism in LSCs by increasing GLS1.</p>Formula:C23H26N10O3Color and Shape:SolidMolecular weight:490.518LSD1-IN-15
<p>LSD1-IN-15 inhibits LSD1, MAO-A/B with IC50s: 0.149, 0.028, 0.327 μM; arrests LNCaP cancer cell growth, IC50 9.9 μM.</p>Formula:C22H20N2OColor and Shape:SolidMolecular weight:328.41JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Color and Shape:SolidGDC-0339
CAS:<p>GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.</p>Formula:C20H22F3N7OSColor and Shape:SolidMolecular weight:465.5PARP-1/HDAC-IN-1
CAS:<p>PARP-1/HDAC-IN-1 is a PARP-1 and HDAC6 inhibitor with anticancer, antimigratory, and antiangiogenic activities and is used in tumor research.</p>Formula:C22H18N4O4Purity:95.94%Color and Shape:SolidMolecular weight:402.4PRMT5-MTA-IN-3
CAS:<p>PRMT5-MTA-IN-3 (Compound P2A) is an orally active and selective inhibitor of protein arginine methyltransferase 5 (PRMT5). It inhibits the proliferation of MTAP-deficient colorectal cancer HCT-116 cell line with an IC50 value of 5 nM. PRMT5-MTA-IN-3 holds potential for research in cancers, particularly in MTAP-deficient tumors such as colorectal cancer, non-small cell lung cancer, and pancreatic cancer.</p>Formula:C19H17F3N6O3Color and Shape:SolidMolecular weight:434.372Pociredir
CAS:<p>Pociredir (FTX-6058), a potent EED inhibitor (KD=0.163 nM), may help in SCD research.</p>Formula:C22H18FN5O2Color and Shape:SolidMolecular weight:403.41LSD1-IN-22
<p>LSD1-IN-22: potent LSD1 inhibitor, K_i 98 nM, curbs cancer cell growth.</p>Formula:C9H8BrF2NColor and Shape:SolidMolecular weight:248.07I-BET282E
<p>I-BET282E inhibits eight BET bromodomains (pIC50 6.4-7.7) with selectivity for other bromodomain proteins.</p>Formula:C26H34N4O7SColor and Shape:SolidMolecular weight:546.64MS117
<p>MS117 is a first-in-class and cell-active irreversible covalent inhibitor of protein arginine methyltransferase 6 (PRMT6) (IC50 = 18 nM) [1].</p>Formula:C17H22N4OColor and Shape:SolidMolecular weight:298.38
